Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 7/20 | 0.32 |
| ▸ | RET | P07949 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24417943 | 1.00 | HCRTR1 (0.33) | HCRTR1HCRTR2DHODHPDE10AACACB | |
| SCHEMBL29618549 | 0.96 | DHODH (0.34) | HCRTR1HCRTR2DHODHPDE10AACACB | |
| SCHEMBL24417950 | 0.96 | DHODH (0.34) | HCRTR1HCRTR2DHODHPDE10AACACB | |
| SCHEMBL26747330 | 0.94 | DHODH (0.34) | HCRTR1HCRTR2DHODHPDE10AACACB | |
| SCHEMBL29618460 | 0.89 | MRGPRX1 (0.35) | ACACB | |
| SCHEMBL24417519 | 0.89 | MRGPRX1 (0.35) | ACACB | |
| SCHEMBL24417860 | 0.85 | MRGPRX1 (0.36) | HCRTR1HCRTR2ACACBRET | |
| SCHEMBL29618621 | 0.85 | MRGPRX1 (0.36) | HCRTR1HCRTR2ACACBRET | |
| SCHEMBL24417817 | 0.82 | DHODH (0.38) | HCRTR1HCRTR2DHODHPDE10AACACB | |
| SCHEMBL29618602 | 0.82 | DHODH (0.38) | HCRTR1HCRTR2DHODHPDE10AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202818-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2025-01-21 | — | — | US | disclosed |
| US-20240174640-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-05-30 | — | — | US | disclosed |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | Opna Bio SA (CH) | 2023-11-07 | — | — | US | disclosed |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202818-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | HCRTR1 868/4885HCRTR2 766/4885DHODH 972/4885 |
| US-20240174640-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ENTPD1, ADORA2A | HCRTR1 868/4885HCRTR2 766/4885DHODH 972/4885 |
| US-11807626-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ENTPD1, ADORA2A | HCRTR1 868/4885HCRTR2 766/4885DHODH 972/4885 |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ENTPD1, ADORA2A | HCRTR1 877/4885HCRTR2 776/4885DHODH 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.